Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Real-world outcomes of IO & TKIs in mRCC

Neil J. Shah • 17 Feb 2022
GU Cancers 2022
Genitourinary Cancer Kidney Cancer

Neil J. Shah, MBBS, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses real-world clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Neil J. Shah

0:55
The evolving treatment landscape of renal cell carcinoma
Neil J. Shah • 17 Feb 2022
1:45
Real-world outcomes of mRCC in the current IO & TKI era
Neil J. Shah • 18 Feb 2022
0:48
Will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?
Neil J. Shah • 18 Feb 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals